Evidence map›Paper›PMID 34259983›Full record

ArticleInternational journal of clinical oncology2021

Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse.

Hiroshi Yasui, Masayuki Kobayashi, Kota Sato, Kanya Kondoh, Tadao Ishida, Yuta Kaito, Hideto Tamura, Hiroshi Handa, Yutaka Tsukune, Makoto Sasaki and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Progress of modern imaging modalities in multiple myeloma.International journal of hematology · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Hiroshi Yasui *Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Masayuki Kobayashi *Division of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kota SatoDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Kanya KondohDivision of Molecular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yuta KaitoDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Hideto TamuraDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Hiroshi HandaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Yutaka TsukuneDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Makoto SasakiDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Norina TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Junji TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Toyotaka KawamataDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Junya MakiyamaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kazuaki YokoyamaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seiya ImotoHuman Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Arinobu TojoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoichi ImaiDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. imaiyo-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-2938-6133

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) is an incurable hematological malignancy. Despite the introduction of several novel drugs, most patients relapse. Biomarkers to identify the early signs of relapse will make it possible to adjust the therapeutic strategy before the disease worsens. Although understanding genetic changes is important for the treatment of MM, currently known biomarkers of relapse, including serum free-light chains and monoclonal paraproteins, are not associated with genetic changes.

methodsWe therefore performed a multicenter study to examine the usefulness of circulating cell-free DNA (cfDNA) present in the peripheral blood (PB) plasma of patients as a biomarker for MM relapse.

resultsWe identified several driver mutations by combined analysis of next-generation sequencing and existing databases of candidate oncogenes. Furthermore, relapse was detected more sensitively by monitoring the circulating cfDNA with these driver mutations than by conventional serum free-light chain examination.

conclusionThese results suggest the potential utility of cfDNA in the PB plasma of patients as a relevant early biomarker for MM relapse.

Indexed as

Cell-Free Nucleic AcidsMultiple MyelomaBiomarkersHumansMutationNeoplasm Recurrence, LocalPlasmaBiomarkersCell-Free Nucleic AcidsBiomarkerLiquid biopsyMultiple MyelomaNext generation sequencingRelapse

Identifiers

PMID34259983

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.